CXCL13 and myeloid sarcoma: Other biomarkers present in both in serum and CSF that have been proposed for assessing MS disease prognosis include, glial fibrillary acidic protein (a marker of neuronal damage), and inflammation markers osteopontin, CXCL13, and CD163.36